Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01249183 | Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine (REPEVAX) and Influenza Vaccine (VAXIGRIP) in Subjects Aged From 60 Years Old | PHASE3 | COMPLETED | 954 | — | — | Oct 1, 2010 | Sep 1, 2011 | Sep 11, 2017 | 20 | France, Germany |
| Arm | Type | Description |
|---|---|---|
| 1- VAXIGRIP and REPEVAX concomitantly | EXPERIMENTAL | - |
| 2-REPEVAX 28 days after VAXIGRIP | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Concomitant administration | BIOLOGICAL | 1 dose (0.5 mL) of VAXIGRIP and 1 dose (0.5 mL) of REPEVAX in 2 separate injections sites (1 on each arm) |
| Separate administration | BIOLOGICAL | 1 dose (0.5 mL) of VAXIGRIP at Day 0 and 1 dose (0.5 mL) of REPEVAX 28 days later |
Inclusion Criteria: * Adults aged ≥60 years * At least one documented booster dose with a tetanus- and diphtheria-containing vaccine between 5 and 15 years * No influenza vaccine administered during the last 6 months Exclusion Criteria: * Receipt of a booster dose with a tetanus or diphtheria- or...